Yan-Ling Chen1, Xiao-Lin Liu2, Ling Li3. 1. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Ping Hai Road, Suzhou, 215006, Jiangsu, China. 2. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Ping Hai Road, Suzhou, 215006, Jiangsu, China. lxl55@foxmail.com. 3. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 899 Ping Hai Road, Suzhou, 215006, Jiangsu, China. liling3243@sina.com.
Abstract
BACKGROUND: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). METHODS: All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs. RESULTS: A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52-2.28, P < 0.01). For disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS), lower miR-34a expression was related to worse DFS/PFS/RFS with a pooled HR of 1.86 (95% CI: 1.31-2.63, P < 0.01). A significant relation of differentiation/TNM stage/lymphatic metastasis and the expression level of miR-34a was identified. CONCLUSION: This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs.
BACKGROUND: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). METHODS: All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs. RESULTS: A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52-2.28, P < 0.01). For disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS), lower miR-34a expression was related to worse DFS/PFS/RFS with a pooled HR of 1.86 (95% CI: 1.31-2.63, P < 0.01). A significant relation of differentiation/TNM stage/lymphatic metastasis and the expression level of miR-34a was identified. CONCLUSION: This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs.
Authors: Yuxin Hu; Arlene M Correa; Ashraful Hoque; Baoxiang Guan; Fei Ye; Jie Huang; Stephen G Swisher; Tsung Teh Wu; Jaffer A Ajani; Xiao-Chun Xu Journal: Int J Cancer Date: 2011-01-01 Impact factor: 7.396
Authors: Nigel B Jamieson; Douglas C Morran; Jennifer P Morton; Asif Ali; Euan J Dickson; C Ross Carter; Owen J Sansom; T R Jeffry Evans; Colin J McKay; Karin A Oien Journal: Clin Cancer Res Date: 2011-11-23 Impact factor: 12.531